Laserfiche WebLink
Issuance of taxable bonds by CEDA for Robinson Pharma <br />November 4, 2025 <br />Page 2 <br />5 <br />4 <br />1 <br />5 <br />The City of Santa Ana became a member of CEDA in 2015 by adopting City Council <br />Resolution No. 2015-002, authorizing the City to enter into the Joint Powers Agreement <br />that formed CEDA. <br />Through this membership: <br /> <br />The City is represented as one of CEDA’s member jurisdictions. <br />The City may request that CEDA issue bonds for qualifying projects located within <br />Santa Ana. <br />The City retains local control over whether to approve each financing that takes <br />place within its boundaries. <br />Membership does not create any financial or legal obligation for the City. CEDA’s bond <br />issuances are conduit financings, meaning the repayment responsibility lies solely with <br />the private borrower benefiting from the funds, not the City or CEDA’s members. <br />Project Description <br />3130 South Fairview LLC, a California limited liability company, and Robinson Pharma, <br />Inc., a California corporation, are requesting CEDA’s assistance in issuing taxable <br />bonds in an amount not to exceed $40,000,000 to finance, refinance, and/or reimburse <br />the costs associated with the manufacturing facilities located at 3130 South Fairview <br />Street, Santa Ana, California 92704 (the “Property”). <br />Headquartered in Santa Ana for more than 37 years, Robinson Pharma, Inc. is a <br />leading dietary supplement manufacturer with multiple state-of-the-art production and <br />warehouse facilities totaling over one million square feet. Employing more than 870 <br />individuals locally, Robinson Pharma plays a key role in strengthening Santa Ana’s <br />manufacturing sector and enhancing the City’s reputation as a center for advanced <br />manufacturing and innovation. <br />Economically, Robinson Pharma contributes to Santa Ana through significant job <br />creation, capital investment, and ongoing tax revenue. The company’s continued <br />expansion has generated employment opportunities across production, logistics, and <br />administrative fields while supporting local contractors and suppliers. Overall, Robinson <br />Pharma serves as a key anchor business within Santa Ana’s industrial base, enhancing <br />economic stability and growth for the community. The acquisition of the Property will <br />enable Robinson Pharma, Inc. to expand its manufacturing operations within the City of <br />Santa Ana. Following its completion in June 2024 as a speculative construction “spec” <br />development, the building at 3130 South Fairview Street remained vacant until <br />Robinson Pharma expressed interest in expanding its local operations by occupying the <br />subject structure. If its occupancy is ultimately approved, Robinson Pharma would <br />become the new building’s first tenant, ending its 16-month vacancy. <br />Pursuant to Section 91530(f) of the California Industrial Development Financing Act <br />(Title 10 of the California Government Code) and the Joint Exercise of Powers Act   <br />  <br />City Council 22 – 2 11/4/2025